TP53 Inactivation Confers Resistance to the Menin Inhibitor Revumenib in Acute Myeloid Leukemia
Jeevitha D’Souza, Camille J. Leung, Aishwarya C. Ballapuram, Abigail S. Lin, Alexa Rane Batingana, Adam J. Lamble, Rhonda E. Ries, Carolina E. Morales, Charisa Cottonham, Pranav Gona, Li Fan, Xiaotu Ma, Kevin Shannon, Soheil Meshinchi, Benjamin S. Braun, Benjamin J. Huang
This study shows TP53 mutations cause resistance to revumenib in AML and suggests combining MCL-1 inhibitors with menin inhibitors could be effective.
bioRxiv · Mar 24, 2025 · PreprintCancer Biology